Vir Biotechnology (VIR) Debt to Equity (2019 - 2025)

Vir Biotechnology has disclosed Debt to Equity across 5 years of filings, most recently posting $0.02 for Q1 2025.

• Debt to Equity for Q1 2025 came in at $0.02, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $0.02 (changed N/A YoY), and the FY2024 annual result was $0.01, changed N/A from the prior year.
• Debt to Equity came in at $0.02 for Q1 2025 at Vir Biotechnology, up from $0.01 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.08 in Q3 2021 to a low of $0.01 in Q4 2024.
• The 3-year median for Debt to Equity is $0.04 (2021), against an average of $0.04.
• Peak annual rise in Debt to Equity reached 326.24% in 2021, while the deepest fall reached 33.24% in 2021.
• Vir Biotechnology's Debt to Equity stood at $0.08 in 2021, then plunged by 82.14% to $0.01 in 2024, then advanced by 20.09% to $0.02 in 2025.
• The last three Debt to Equity figures came in at $0.02 (Q1 2025), $0.01 (Q4 2024), and $0.08 (Q3 2021), per Business Quant data.